目的：了解慢性乙型肝炎病毒携带者的肝组织病理改变、乙型肝炎再激活率等。
Objective:To investigate the turnover of hepatic tissue pathology, hepatitis B reactivation rate in chronic HBV carriers.
目的探讨细胞免疫在慢性乙型肝炎病毒（HBV）感染中的作用和干扰素治疗对细胞免疫的影响。
Objective To explore the action of cellular immunity in chronic HBV infection and the effect of interferon.
这些基本而又不同的治疗选择每一种均具有一定的优势和局限性在抗慢性乙型肝炎病毒中具有一定定位。
Each of these fundamentally different approaches has advantages and limitations and both have a place in the therapeutic armamentarium against chronic hepatitis b.
原发性肝癌(HCC)是目前世界上十大恶性肿瘤之一，而慢性乙型肝炎病毒(HBV)感染是导致HCC最主要的原因之一。
Primary hepatocellular carcinoma (HCC) is one of the top 10 malignant tumors worldwide, and chronic infection with HBV is one of the major causes of HCC.
例如，在慢性乙型肝炎病毒和艾滋病病毒治疗期间发生艾滋病毒感染和耐药变异时CXCR 4向性病毒的出现可作为这种持续演变的表型证据。
Phenotypic evidence of this continuing evolution is seen, for example, in the emergence of CXCR4 tropic viruses during HIV infection and drug-resistant variants during chronic HBV and HIV therapy.
乙型肝炎病毒(造成肝炎，慢性肝炎可导致肝癌)。
Hepatitis B virus (causes hepatitis and chronic cases may lead to cancer of the liver).
全世界每三人中就有将近一人感染乙肝病毒(约20亿人)，而每十二人中就有一人(5.2亿多人)的生活与慢性乙型肝炎或慢性乙肝病毒感染相伴。
Nearly one out of every three people in the world (approximately 2 billion people) has been infected by HBV, and one in twelve (more than 520 million people) live with chronic HBV or HCV infection.
慢性乙型肝炎是否发病及发病的严重程度与病毒因素和宿主因素的共同作用有关。
It is generally accepted that virus factors and host factors are both important in the exacerbation and severity of chronic hepatitis b.
结论护理干预可提高慢性乙型肝炎患者抗病毒治疗的依从性。
Conclusion Using nursing intervention was an effective method for raising the therapeutic compliance of patients with chronic hepatitis B.
目的：探讨慢性乙型肝炎肝纤维化与肝功能、病毒定量之间的关系，为临床预测疾病的严重程度提供依据。
Objective: To research the reference of Chronic hepatitis B fibrosis with liver function and rivus quantitation, and provide the evidence for clinic to estimate the disease severity degree.
目的探讨慢性乙型肝炎患者抗病毒治疗与血清脂质水平的关系。
Objective To investigate the relationship between anti-virus therapy and blood fat levels in hepatitis patients.
在我国，乙型肝炎病毒(HBV)相关的急慢性终末期肝病逐渐成为肝移植的主要适应症。
In our country, acute or chronic HBV-related end-stage liver diseases serve as the main indication of the liver transplantation, which is likely to bring about the reinfection of HBV post-LT.
结论治疗前较高的ALT水平，较低的HBVDNA定量值及出现早期病毒学应答是影响拉米夫定治疗慢性乙型肝炎疗效的主要因素。
Conclusions the relatively high ALT level, low HBV DNA ration and early virus response are the major factors that affect the curative effect of lamivudine in treating chronic hepatitis B.
结论苦参素与黄芪注射液具有良好的保肝、抗乙肝病毒、抗肝纤维化作用，治疗慢性乙型肝炎疗效确切。
Conclusion the combination of matrine and astragalus injection has satisfactory actions of protecting liver, anti-HBV and anti-fibrosis in the treatment of chronic hepatitis b.
目的研究乙型肝炎（乙肝）病毒核心基因内缺失突变株（ C I D）在慢性乙肝及肝癌患者中存在的状态及意义。
Objective To study the status and significance of hepatitis B virus core internal deletion (CID) mutants in chronic hepatitis B and hepatocellular carcinoma patients.
HBV的这些病毒学特点与乙型肝炎的慢性化和疾病进展密切相关。
The virological characteristics of HBV are closely related with the chronicity and disease course of hepatitis B.
目的观察拉米夫定治疗儿童慢性乙型肝炎的临床疗效及对乙肝病毒标志物的影响。
Objective To observe the clinic effect of lamivudine in children with chronic hepatitis B and its influence of HBV markers.
旨在提高和保持拉米夫定在慢性乙型肝炎抗病毒治疗的效果。
The objective is to improve and maintain the antiviral treatment efficacy of lamivudine in chronic hepatitis B.
目的对比研究同一慢性乙型肝炎患者拉米夫定治疗前及病情急性恶化后乙型肝炎病毒（HBV）株的结构基因组。
Objective To compare the structural genome variations of lamivudine resistant HBV strain from a patient with acute exacerbation after lamivudine therapy with pretretment HBV strain.
慢性肝病患者绝大多数已被乙型肝炎病毒(HBV)感染。
Most of the patients with chronic liver diseases were infected with hepatitis B virus (HBV).
目的：观察慢性乙型肝炎（慢乙肝）患者细胞因子及病毒指标与中医证型的关系。
Objective:To explore the correlation between different syndrome types of TCM and serum cytokines and replication of Virus index in chronic hepatitis B(CHB).
联合变异株主要见于重度慢性乙型肝炎患者，与血清病毒含量无关。
The united mutations often occurred in patients with severe chronic hepatitis B, and been not related to the viral load.
建立乙型肝炎病毒变异基因诊断芯片对拉米夫定治疗慢性乙型肝炎过程中出现的肝炎病毒P基因区YMDD变异进行快速准确的检测方法。
To set up using the gene chip technology to detect and identify quickly and accurately the HBV P gene YMDD Motif mutation during the chronic hepatitis treated with lamivudine.
目的探讨GB病毒C（GBV -C）的致病性，以及混合感染GBV -C后对慢性乙型肝炎及慢性丙型肝炎预后的影响。
Objective To study the pathogenicity of GB virus C(GBV-C), and effect of coinfection with GBV-C on hepatitis B and C.
因此，治疗慢性病毒性乙型肝炎是我们当前所面临的一个艰巨使命。
Therefore, the treatment of chronic hepatitis B is currently facing a difficult mission.
乙型肝炎病毒(HBV)是人类急慢性肝炎、肝硬化和肝细胞癌的主要病因。
Hepatitis B virus (HBV) is a major cause of acute and chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma in humans.
恩替卡韦治疗慢性乙型肝炎：大多数的部分病毒学应答初治患者无需剂量调整。
Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naive patients with a partial virological response...
维持性血液透析(血透)患者乙型肝炎病毒(HBV)感染率明显高于健康人群和慢性肾脏病非透析患者。
Incidence of hepatitis B virus (HBV) infection is much higher in maintenance hemodialysis (HD) patients than that in healthy controls or other chronic kidney disease patients who do not need HD.
经过临床多年实践表明，该方治疗慢性病毒性乙型肝炎的临床疗效显著，而且经济、安全，深受广大患者好评。
After years of clinical practice showed that the treatment of chronic hepatitis B, the clinical efficacy significantly, and economic, security, in patients with widespread praise.
中医药在治疗慢性病毒性乙型肝炎方面具有“简、便、廉、验”的优势，是我国治疗慢性病毒性乙型肝炎的特色与优势。
Chinese medicine in the treatment of chronic hepatitis B has "Jane, we, inexpensive and postmortem" advantage is the treatment of chronic hepatitis B in China's characteristics and advantages.
应用推荐